The Therapy of Peri-implantitis: A Systematic Review

被引:301
作者
Heitz-Mayfield, Lisa J. A. [1 ]
Mombelli, Andrea [2 ]
机构
[1] Univ Western Australia, Int Res Collaborat, Nedlands, WA 6009, Australia
[2] Univ Geneva, Sch Dent Med, Div Periodontol & Oral Pathophysiol, Geneva, Switzerland
关键词
peri-implantitis; systematic review; treatment; therapy; LOCAL-DRUG DELIVERY; ANTIINFECTIVE MECHANICAL THERAPY; 3-YEAR CLINICAL-TRIAL; SHAPED ORAL IMPLANTS; AIR-ABRASIVE DEVICE; NONSURGICAL TREATMENT; SURGICAL THERAPY; NANOCRYSTALLINE HYDROXYAPATITE; REGENERATIVE TREATMENT; RESECTIVE SURGERY;
D O I
10.11607/jomi.2014suppl.g5.3
中图分类号
R78 [口腔科学];
学科分类号
100302 [口腔临床医学];
摘要
Purpose: To evaluate the success of treatments aimed at the resolution of peri-implantitis in patients with osseointegrated implants. Materials and Methods: The potentially relevant literature was assessed independently by two reviewers to identify case series and comparative studies describing the treatment of peri-implantitis with a follow-up of at least 3 months. Medline, Embase, and The Cochrane Library were searched. For the purposes of this review, a composite criterion for successful treatment outcome was used which comprised implant survival with mean probing depth < 5 mm and no further bone loss. Results: A total of 43 publications were included: 4 papers describing 3 nonsurgical case series, 13 papers describing 10 comparative studies of nonsurgical interventions, 15 papers describing 14 surgical case series, and 11 papers describing 6 comparative studies of surgical interventions. No trials comparing nonsurgical with surgical interventions were found. The length of follow-up varied from 3 months to 7.5 years. Due to the heterogeneity of study designs, peri-implantitis case definitions, outcome variables, and reporting, no meta-analysis was performed. Eleven studies could be evaluated according to a composite success criterion. Successful treatment outcomes at 12 months were reported in 0% to 100% of patients treated in 9 studies and in 75% to 93% of implants treated in 2 studies. Commonalities in treatment approaches between studies included (1) a pretreatment phase, (2) cause-related therapy, and (3) a maintenance care phase. Conclusions: While the available evidence does not allow any specific recommendations for the therapy of peri-implantitis, successful treatment outcomes at 12 months were reported in a majority of patients in 7 studies. Although favorable short-term outcomes were reported in many studies, lack of disease resolution as well as progression or recurrence of disease and implant loss despite treatment were also reported. The reported outcomes must be viewed in the context of the varied peri-implantitis case definitions and severity of disease included as well as the heterogeneity in study design, length of follow-up, and exclusion/inclusion criteria.
引用
收藏
页码:325 / 345
页数:21
相关论文
共 60 条
[1]
Aughtun M., 1992, Zeitschrift Fur Zahnarzuche Implantologir, V8, P246
[2]
Bach G, 2000, Implant Dent, V9, P247, DOI 10.1097/00008505-200009030-00010
[3]
Behneke A, 2000, INT J ORAL MAX IMPL, V15, P125
[4]
Bornstein MM, 2009, INT J ORAL MAX IMPL, V24, P12
[5]
Sustained release of doxycycline for the treatment of peri-implantitis:: randomised controlled trial [J].
Büchter, A ;
Meyer, U ;
Kruse-Lösler, B ;
Joos, U ;
Kleinheinz, J .
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2004, 42 (05) :439-444
[6]
A follow-up study of peri-implantitis cases after treatment [J].
Charalampakis, Georgios ;
Rabe, Per ;
Leonhardt, Asa ;
Dahlen, Gunnar .
JOURNAL OF CLINICAL PERIODONTOLOGY, 2011, 38 (09) :864-871
[7]
Tumor Necrosis Factor-Alpha Levels After Surgical Anti-infective Mechanical Therapy for Peri-Implantitis: A 12-Month Follow-Up [J].
de Mendonca, Adriana Cutrim ;
Santos, Vanessa Renata ;
Cesar-Neto, Joao Batista ;
Duarte, Poliana Mendes .
JOURNAL OF PERIODONTOLOGY, 2009, 80 (04) :693-699
[8]
Deppe H, 2007, INT J ORAL MAX IMPL, V22, P79
[9]
Duarte PM, 2009, J PERIODONTOL, V80, P234, DOI [10.1902/jop.2009.070672, 10.1902/jop.2009.070672 ]
[10]
Esposito M, 2012, EUR J ORAL IMPLANTOL, V5, pS21